vs

Side-by-side financial comparison of UNIVERSAL TECHNICAL INSTITUTE INC (UTI) and Zai Lab Ltd (ZLAB). Click either name above to swap in a different company.

UNIVERSAL TECHNICAL INSTITUTE INC is the larger business by last-quarter revenue ($220.8M vs $127.1M, roughly 1.7× Zai Lab Ltd). On growth, Zai Lab Ltd posted the faster year-over-year revenue change (17.1% vs 9.6%). UNIVERSAL TECHNICAL INSTITUTE INC produced more free cash flow last quarter ($-19.2M vs $-26.7M). Over the past eight quarters, Zai Lab Ltd's revenue compounded faster (20.8% CAGR vs 9.5%).

Universal Technical Institute, Inc. (UTI) is a private for-profit system of technical colleges in the United States. It was established in 1965 by Robert Sweet.

Zai Lab Ltd is a global biopharmaceutical company focused on developing, manufacturing and commercializing innovative therapies for oncology, autoimmune disorders, infectious diseases and other unmet medical needs. It operates primarily in the Greater China region and partners with leading global biotech firms to expand access to life-saving treatments for underserved patient populations.

UTI vs ZLAB — Head-to-Head

Bigger by revenue
UTI
UTI
1.7× larger
UTI
$220.8M
$127.1M
ZLAB
Growing faster (revenue YoY)
ZLAB
ZLAB
+7.5% gap
ZLAB
17.1%
9.6%
UTI
More free cash flow
UTI
UTI
$7.5M more FCF
UTI
$-19.2M
$-26.7M
ZLAB
Faster 2-yr revenue CAGR
ZLAB
ZLAB
Annualised
ZLAB
20.8%
9.5%
UTI

Income Statement — Q1 FY2026 vs Q4 FY2025

Metric
UTI
UTI
ZLAB
ZLAB
Revenue
$220.8M
$127.1M
Net Profit
$12.8M
Gross Margin
51.0%
Operating Margin
7.1%
-54.6%
Net Margin
5.8%
Revenue YoY
9.6%
17.1%
Net Profit YoY
-42.1%
EPS (diluted)
$0.23
$-0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
UTI
UTI
ZLAB
ZLAB
Q4 25
$220.8M
$127.1M
Q3 25
$222.4M
$115.4M
Q2 25
$204.3M
$109.1M
Q1 25
$207.4M
$105.7M
Q4 24
$201.4M
$108.5M
Q3 24
$196.4M
$101.8M
Q2 24
$177.5M
$100.1M
Q1 24
$184.2M
$87.1M
Net Profit
UTI
UTI
ZLAB
ZLAB
Q4 25
$12.8M
Q3 25
$18.8M
$-36.0M
Q2 25
$10.7M
$-40.7M
Q1 25
$11.4M
$-48.4M
Q4 24
$22.2M
Q3 24
$18.8M
$-41.7M
Q2 24
$5.0M
$-80.3M
Q1 24
$7.8M
$-53.5M
Gross Margin
UTI
UTI
ZLAB
ZLAB
Q4 25
51.0%
Q3 25
59.5%
Q2 25
60.6%
Q1 25
63.6%
Q4 24
61.5%
Q3 24
64.1%
Q2 24
64.9%
Q1 24
61.4%
Operating Margin
UTI
UTI
ZLAB
ZLAB
Q4 25
7.1%
-54.6%
Q3 25
11.2%
-42.3%
Q2 25
6.9%
-50.3%
Q1 25
8.1%
-53.3%
Q4 24
13.6%
-62.6%
Q3 24
13.3%
-66.6%
Q2 24
4.2%
-76.0%
Q1 24
6.1%
-80.7%
Net Margin
UTI
UTI
ZLAB
ZLAB
Q4 25
5.8%
Q3 25
8.4%
-31.2%
Q2 25
5.2%
-37.3%
Q1 25
5.5%
-45.8%
Q4 24
11.0%
Q3 24
9.6%
-40.9%
Q2 24
2.8%
-80.2%
Q1 24
4.2%
-61.4%
EPS (diluted)
UTI
UTI
ZLAB
ZLAB
Q4 25
$0.23
$-0.05
Q3 25
$0.33
$-0.03
Q2 25
$0.19
$-0.04
Q1 25
$0.21
$-0.04
Q4 24
$0.40
$-0.09
Q3 24
$0.35
$-0.04
Q2 24
$0.09
$-0.08
Q1 24
$0.14
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
UTI
UTI
ZLAB
ZLAB
Cash + ST InvestmentsLiquidity on hand
$162.8M
$689.6M
Total DebtLower is stronger
$101.4M
Stockholders' EquityBook value
$335.9M
$715.5M
Total Assets
$834.0M
$1.2B
Debt / EquityLower = less leverage
0.30×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
UTI
UTI
ZLAB
ZLAB
Q4 25
$162.8M
$689.6M
Q3 25
$169.1M
$717.2M
Q2 25
$70.7M
$732.2M
Q1 25
$96.0M
$757.3M
Q4 24
$172.0M
$779.7M
Q3 24
$161.9M
$616.1M
Q2 24
$115.5M
$630.0M
Q1 24
$116.1M
$650.8M
Total Debt
UTI
UTI
ZLAB
ZLAB
Q4 25
$101.4M
Q3 25
$87.1M
Q2 25
$73.8M
Q1 25
$94.4M
Q4 24
$120.1M
Q3 24
$125.7M
Q2 24
$137.3M
Q1 24
$141.9M
Stockholders' Equity
UTI
UTI
ZLAB
ZLAB
Q4 25
$335.9M
$715.5M
Q3 25
$328.1M
$759.9M
Q2 25
$306.8M
$791.7M
Q1 25
$293.9M
$810.8M
Q4 24
$280.0M
$840.9M
Q3 24
$260.2M
$667.7M
Q2 24
$239.4M
$704.2M
Q1 24
$232.6M
$762.2M
Total Assets
UTI
UTI
ZLAB
ZLAB
Q4 25
$834.0M
$1.2B
Q3 25
$826.1M
$1.2B
Q2 25
$740.8M
$1.2B
Q1 25
$720.4M
$1.2B
Q4 24
$753.8M
$1.2B
Q3 24
$744.6M
$985.3M
Q2 24
$706.0M
$987.4M
Q1 24
$702.1M
$988.4M
Debt / Equity
UTI
UTI
ZLAB
ZLAB
Q4 25
0.30×
Q3 25
0.27×
Q2 25
0.24×
Q1 25
0.32×
Q4 24
0.43×
Q3 24
0.48×
Q2 24
0.57×
Q1 24
0.61×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
UTI
UTI
ZLAB
ZLAB
Operating Cash FlowLast quarter
$3.1M
$-26.0M
Free Cash FlowOCF − Capex
$-19.2M
$-26.7M
FCF MarginFCF / Revenue
-8.7%
-21.0%
Capex IntensityCapex / Revenue
10.1%
0.5%
Cash ConversionOCF / Net Profit
0.24×
TTM Free Cash FlowTrailing 4 quarters
$16.6M
$-158.9M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
UTI
UTI
ZLAB
ZLAB
Q4 25
$3.1M
$-26.0M
Q3 25
$57.1M
$-32.0M
Q2 25
$18.1M
$-31.0M
Q1 25
$-789.0K
$-61.7M
Q4 24
$23.0M
$-55.8M
Q3 24
$67.5M
$-26.8M
Q2 24
$10.0M
$-42.2M
Q1 24
$-2.5M
$-90.1M
Free Cash Flow
UTI
UTI
ZLAB
ZLAB
Q4 25
$-19.2M
$-26.7M
Q3 25
$40.6M
$-35.0M
Q2 25
$6.8M
$-33.9M
Q1 25
$-11.7M
$-63.2M
Q4 24
$19.6M
$-58.4M
Q3 24
$60.0M
$-28.2M
Q2 24
$3.0M
$-42.9M
Q1 24
$-8.4M
$-91.1M
FCF Margin
UTI
UTI
ZLAB
ZLAB
Q4 25
-8.7%
-21.0%
Q3 25
18.3%
-30.4%
Q2 25
3.4%
-31.1%
Q1 25
-5.7%
-59.9%
Q4 24
9.7%
-53.8%
Q3 24
30.6%
-27.7%
Q2 24
1.7%
-42.9%
Q1 24
-4.6%
-104.5%
Capex Intensity
UTI
UTI
ZLAB
ZLAB
Q4 25
10.1%
0.5%
Q3 25
7.4%
2.6%
Q2 25
5.5%
2.6%
Q1 25
5.3%
1.5%
Q4 24
1.7%
2.4%
Q3 24
3.8%
1.3%
Q2 24
4.0%
0.7%
Q1 24
3.2%
1.1%
Cash Conversion
UTI
UTI
ZLAB
ZLAB
Q4 25
0.24×
Q3 25
3.04×
Q2 25
1.69×
Q1 25
-0.07×
Q4 24
1.04×
Q3 24
3.58×
Q2 24
2.01×
Q1 24
-0.32×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

UTI
UTI

UTI$142.8M65%
Concorde$78.0M35%

ZLAB
ZLAB

Zejula$56.0M44%
Other$21.9M17%
Nuzyra$16.0M13%
Optune$11.9M9%
XACDURO$10.7M8%
Qinlock$9.7M8%
AUGTYRO$836.0K1%

Related Comparisons